Advertisement


Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Issues in Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Cost of Care

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Advertisement